Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

SBC Medical Group Holdings (SBC) EBITDA (2023 - 2025)

SBC Medical Group Holdings filings provide 3 years of EBITDA readings, the most recent being -$377406.0 for Q4 2025.

  • On a quarterly basis, EBITDA rose 96.73% to -$377406.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $48.1 million, a 60.44% increase, with the full-year FY2025 number at $47.9 million, up 58.86% from a year prior.
  • EBITDA hit -$377406.0 in Q4 2025 for SBC Medical Group Holdings, down from $6.0 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $31.3 million in Q1 2025 to a low of -$11.6 million in Q4 2024.
  • Median EBITDA over the past 3 years was $7.7 million (2023), compared with a mean of $8.8 million.
  • The widest YoY moves for EBITDA: up 2302.71% in 2024, down 152.16% in 2024.
  • SBC Medical Group Holdings' EBITDA stood at $22.1 million in 2023, then plummeted by 152.16% to -$11.6 million in 2024, then surged by 96.73% to -$377406.0 in 2025.
  • The last three reported values for EBITDA were -$377406.0 (Q4 2025), $6.0 million (Q3 2025), and $11.1 million (Q2 2025) per Business Quant data.